Compound Evidence File
#EC-2026-0199
BPC-157 Arg Oral
Filed under Oral Tablets. The bureau holds 140 laboratory returns for this compound from 48 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
48 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 10.0 | 9.9 | 10.0 | 13 Mar 2026 | 24 May 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 10.0 | 9.9 | 10.0 | 12 Jun 2026 | 5 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 10.0 | 9.9 | 10.0 | 18 May 2026 | 15 Aug 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 5 Feb 2026 | 16 May 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 6 Mar 2026 | 9 Jul 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 10.0 | 10.0 | 10.0 | 19 Feb 2026 | 11 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 10.0 | 10.0 | 10.0 | 17 Jun 2026 | 19 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 10.0 | 10.0 | 10.0 | 11 May 2026 | 14 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 10.0 | 10.0 | 10.0 | 10 Mar 2026 | 4 Apr 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 10.0 | 10.0 | 10.0 | 12 May 2026 | 3 Jun 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 4 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 9.9 | 9.9 | 10.0 | 28 Nov 2025 | 18 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 4 | 9.9 | 9.9 | 10.0 | 1 May 2026 | 13 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Apr 2026 | 16 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 9.9 | 9.9 | 10.0 | 1 May 2026 | 22 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 3 | 9.9 | 9.9 | 9.9 | 3 Nov 2025 | 10 Apr 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 3 | 9.9 | 9.9 | 10.0 | 21 May 2026 | 17 Jul 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 2 | 9.9 | 9.9 | 10.0 | 12 Jan 2026 | 17 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 9.9 | 20 Jan 2026 | 6 Mar 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 5 Jan 2026 | 14 Feb 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 9.9 | 8 Jan 2026 | 17 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 24 Jul 2026 | 19 Aug 2026 |
| ScienceCASE #VI-2026-0636 | X | 1 | 9.8 | 9.8 | 9.8 | 24 Apr 2025 | 24 Apr 2025 |
| TSC Top Supplements ChinaCASE #VI-2026-0523 | X | 1 | 9.6 | 9.6 | 9.6 | 11 Jun 2025 | 11 Jun 2025 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 8.7 | 7.8 | 9.5 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.2 | 7.4 | 9.2 | 24 May 2026 | 24 May 2026 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 1 | 8.2 | 8.2 | 8.2 | 13 Jun 2025 | 13 Jun 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 3 | 8.1 | 7.7 | 8.7 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 7.8 | 6.8 | 8.9 | 25 May 2026 | 25 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 7.6 | 6.1 | 8.8 | 24 May 2026 | 24 May 2026 |
| Zhejiang Yichenkang BiotechnologyCASE #VI-2026-0269 | X | 1 | 7.2 | 7.2 | 7.2 | 21 May 2025 | 21 May 2025 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 7.2 | 7.2 | 7.2 | 2 Jul 2025 | 2 Jul 2025 |
| NexaphCASE #VI-2026-0944 | X | 13 | 7.0 | 3.2 | 9.7 | 24 Apr 2025 | 17 May 2026 |
| Peptide HavenCASE #VI-2026-0898 | X | 1 | 7.0 | 7.0 | 7.0 | 14 Jan 2025 | 14 Jan 2025 |
| Nuscience PeptidesCASE #VI-2026-0554 | X | 4 | 6.7 | 5.1 | 9.6 | 6 May 2025 | 24 May 2026 |
| Peptronix Bio PTBCASE #VI-2026-0979 | X | 1 | 6.7 | 6.7 | 6.7 | 25 Apr 2025 | 25 Apr 2025 |
| Planet PeptideCASE #VI-2026-0092 | X | 4 | 6.4 | 5.2 | 8.7 | 21 May 2025 | 21 May 2026 |
| BeiBangAnCASE #VI-2026-0899 | X | 3 | 6.4 | 3.5 | 9.2 | 3 Jun 2025 | 23 May 2026 |
| Evolve BioPepCASE #VI-2026-0755 | X | 1 | 6.3 | 6.3 | 6.3 | 25 Apr 2025 | 25 Apr 2025 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 1 | 5.9 | 5.9 | 5.9 | 24 Apr 2025 | 24 Apr 2025 |
| Platinum CryoCASE #VI-2026-0406 | X | 2 | 5.7 | 5.6 | 5.7 | 17 Dec 2024 | 24 May 2026 |
| LN PeptidesCASE #VI-2026-0781 | X | 1 | 5.6 | 5.6 | 5.6 | 11 Jun 2025 | 11 Jun 2025 |
| Peptide GurusCASE #VI-2026-0854 | X | 3 | 4.5 | 3.5 | 5.7 | 11 Jun 2025 | 21 May 2026 |
| Xingtai Lesda TechnologyCASE #VI-2026-0381 | X | 1 | 4.4 | 4.4 | 4.4 | 16 Mar 2025 | 16 Mar 2025 |
| Pharma Grade PeptidesCASE #VI-2026-0208 | X | 1 | 4.3 | 4.3 | 4.3 | 20 Jun 2025 | 20 Jun 2025 |
| Hebei Chengtong TechnologyCASE #VI-2026-0520 | X | 1 | 2.0 | 2.0 | 2.0 | 3 Jun 2025 | 3 Jun 2025 |
| PRIVATECASE #VI-2026-0635 | X | 1 | 0.8 | 0.8 | 0.8 | 28 Mar 2025 | 28 Mar 2025 |
Open any subject to view the batch-level evidence for BPC-157 Arg Oral alone.